Outcomes of Using IVC Filters in Patients with Malignancy at an Academic Medical Center

Abstract

Systemic anticoagulation is regarded as optimal treatment and prophylaxis of venous thromboembolism (VTE). In malignancy, bleeding risk is increased while the patients remain hypercoagulable, making anticoagulation management troublesome. Inferior vena cava (IVC) filters have emerged as an option in the management of VTE, especially when anticoagulant agents are contraindicated. There is limited data on the overall outcomes of patients with malignancy and IVC filter placement. This descriptive study identifies individuals with filters placed and reviews outcomes to guide appropriate care of patients with malignancy and VTE. We performed a retrospective chart review of 115 patients with malignancy who had a filter placed between July 2014 and December 2016. Eighty-seven patients were tracked until December 2017 for significant events (VTE and/or death). In total, 61% (n = 70) had metastatic solid tumor malignancy and 77% (n = 88) were receiving anticoagulation therapy prior to IVC filter placement. Fifty-three percent (n = 61) had bleeding events and 25% (n = 29) had thrombocytopenia. Patients with isolated solid tumors receiving frequent surgery were also common recipients of filters. Sixty-six percent (57/87) of patients had a significant event; 85% of them were anticoagulated. Eighty-two percent of events occurred within 6 months of filter placement, with death occurring on average within 5 months of placement. Overall, use of IVC filters was more common in cancer patients who developed bleeding complications on anticoagulation and with metastatic malignancy. However, in patients with metastatic or hematologic disease, filter placement did not prevent all-cause mortality. Individualized risk–benefit consideration is needed before IVC filters are placed.

Keywords

anticoagulation therapy - cancer - thrombosis - survival - outcomes

• References

• 1 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
• 2 Lee AYY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107 (23) (Suppl. 01) I17-I21
• 3 Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002; 87 (06) 1076-1077
• 4 Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist 2004; 9 (05) 561-570
• 5 Schwarz RE, Marrero AM, Conlon KC, Burt M. Inferior vena cava filters in cancer patients: indications and outcome. J Clin Oncol 1996; 14 (02) 652-657
• 6 Kaufman JA, Kinney TB, Streiff MB. , et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol 2006; 17 (03) 449-459
• 7 Prandoni P, Lensing AW, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
• 8 Ingber S, Geerts WH. Vena caval filters: current knowledge, uncertainties and practical approaches. Curr Opin Hematol 2009; 16 (05) 402-406
• 9 Lim MY, Yamada R, Guimaraes M, Greenberg CS. Practice patterns of inferior vena cava filter placement and factors that predict retrieval rates: a single-center institution and review of the literature. J Clin Med Res 2018; 10 (10) 758-764
• 10 PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112 (03) 416-422
• 11 Jarrett BP, Dougherty MJ, Calligaro KD. Inferior vena cava filters in malignant disease. J Vasc Surg 2002; 36 (04) 704-707
• 12 Barginear MF, Lesser M, Akerman ML. , et al. Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome. Clin Appl Thromb Hemost 2009; 15 (03) 263-269
• 13 Zerati AE, Wolosker N, Yazbek G, Langer M, Nishinari K. Vena cava filters in cancer patients: experience with 50 patients. Clinics (São Paulo) 2005; 60 (05) 361-366
• 14 Schunn C, Schunn GB, Hobbs G, Vona-Davis LC, Waheed U. Inferior vena cava filter placement in late-stage cancer. Vasc Endovascular Surg 2006; 40 (04) 287-294
• 15 Ihnat DM, Mills JL, Hughes JD, Gentile AT, Berman SS, Westerband A. Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine?. J Vasc Surg 1998; 28 (05) 800-807
• 16 Rojas-Hernandez CM, Zapata-Copete JA, García-Perdomo HA. Role of vena cava filters for the management of cancer-related venous thromboembolism: systematic review and meta-analysis. Crit Rev Oncol Hematol 2018; 130: 44-50